Breaking News, Financial News

J&J 4Q Revenues up 7%

Growth driven by DARZALEX, ERLEADA, TECVAYLI, CARVYKTI, STELARA, TREMFYA, and SPRAVATO.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson 4Q Revenues: $21.4 billion (+7%) 4Q Earnings: $4.1 billion (+28%) FY Revenues: $85.2 billion (+6.5) FY Earnings: $13.3 billion (-18.6%) Comments: Innovative Medicine worldwide operational sales grew 5% in the quarter. Growth was driven by DARZALEX (daratumumab) with sales up 22% to $2.6 billion, ERLEADA (apalutamide) with sales up 20% to $647 million, TECVAYLI (teclistamab-cqyv) in Other Oncology, and CARVYKTI (ciltacabtagene autoleucel) with sales of $159 million. STE...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters